TVM Healthcare MENA II is a private equity growth expansion fund managed by TVM Capital Healthcare Partners, established in 2015 and based in Dubai, United Arab Emirates. The fund primarily targets investments in the healthcare sector across the Middle East and North Africa, as well as South and Southeast Asia. It focuses on companies that are either leaders or have the potential to become leaders in their respective markets. The firm seeks to invest in various areas within healthcare, including hospitals, clinical services, and pharmaceutical manufacturing, aiming to enhance the quality and efficiency of healthcare delivery. TVM Healthcare MENA II typically prefers to take a majority stake in its portfolio companies and actively participates in governance by taking board seats.
Recurv Pharma's RP-001 is a novel chemical entity (NCE) that is administered in a nano-emulsion formulation, concentrating medication delivery to the tumour while preserving healthy organs. Strong efficacy in a variety of pre-clinical tumour models, including non-small cell lung, breast, ovarian, prostate, pancreatic, and colorectal cancers, has allowed the chemical to show that it can destroy tumours even in multi-drug resistant tumours.
AMILI develops diagnostic tests, predictive algorithms, and microbiome-modifying interventions. They also offer probiotics and diagnostic tests based on their own microbiome database. They also provide faecal microbiota transplants to aid in the treatment of bacterial infections.
Egg Medical is a medical device company that offers EGGNEST, a passive protection designed to drastically reduce scatter radiation exposure for the entire cath lab team without disruption to workflow. It is an in integrated work platform built on a carbon fiber sled base designed to drastically reduce scatter radiation exposure without disrupting workflow.
Centogene AG is a leading genetic biotechnology company based in Rostock, Germany, specializing in genetic and biochemical diagnostic testing for rare hereditary disorders. The company offers a range of services to support the medical community, including genetic counseling, newborn screening, and biomarker analysis for lysosomal storage disorders. Centogene has developed a comprehensive rare disease platform that integrates epidemiologic, phenotypic, and genetic data, along with a biobank of blood samples, to aid in patient diagnosis and treatment. Additionally, the company collaborates with pharmaceutical partners to provide services such as patient recruitment, epidemiological insights, and biomarker discovery. Its diagnostic services are accessible through healthcare providers, facilitating targeted genetic sequencing for patients with various genetic disorders. With operations in multiple countries, including the United States and the United Arab Emirates, Centogene aims to improve awareness and treatment options for patients with rare diseases globally.
Access Vascular has developed a disruptive technology using a novel material process intended to significantly reduce the blood component accumulation (thrombosis or blood clotting) that leads to occlusions and infections. Over the last three years, Access Vascular’s technology has demonstrated the potential for superior clinical outcomes and lower healthcare costs compared with existing technologies. For patients, their solutions are predicted to decrease morbidity, shorten hospital stays, advance treatment, and minimize pain. Their technology has the potential to address a range of clinical needs in a variety of indications. Access Vascular is focused initially on launching their HydroPICC, a peripherally inserted central catheter with superior material performance over the current lagging technology.
Kent Imaging is an innovator in multispectral oxygenation imaging, designs, manufactures, and markets imaging technology to improve plastic surgery, colorectal surgery, trauma, wound care, limb salvage, podiatry, burns, and cardiac specialties. The team at Kent Imaging is committed to improving patient outcomes by delivering innovative and practical solutions for the healthcare industry. Kent Imaging holds multiple patents in medical technology and is currently commercializing the breakthrough multispectral imaging solutions that assess tissue oxygen saturation. The company is headquartered in Calgary, Alberta, Canada, and has locations in Chicago, Los Angeles, Salt Lake City, and Seattle.
Vespina Lifesciences
Venture Round in 2021
Vespina Lifesciences plans to develop to proof-of-concept a potential compound with the potential to treat certain types of inflammatory diseases including pulmonary indications with poor therapeutic options as well as non-pulmonary inflammatory diseases. The compound was originally discovered and characterized at Denmark-based Neuprozyme Therapeutics ApS. There are upwards of 70,000 patients newly diagnosed with bronchiectasis in the US every year as more than half of the 16+ million patients diagnosed with COPD in the US likely also have concurrent bronchiectasis. There are no approved treatments that specifically address the underlying mechanism of disease.
ImmunoRx Pharma
Acquisition in 2021
ImmunoRx Pharma develops an anti-body that treats certain types of chronic inflammatory diseases including ulcerative colitis, rheumatoid arthritis, and Crohn’s disease. The company's antibody targets a new critical target in chronic inflammation and auto-immunity which was originally discovered by Dr. Tessier in Canada.
leon nanodrugs a specialised product development company dedicated to developing a pipeline of enhanced versions of existing drug products, and providing services to enable pre-clinical and clinical stage formulations for their clients NCEs or branded established drugs. leon-nanodrugs offers access to the next generation of nano-formulated drugs with meaningful differentiation and added patient benefits. They specialize in improving the bioavailability of poorly water soluble drugs by using leon’s proprietary MJR® Technology platform to create either polymeric or crystalline nanoparticles.
Emovi is a company offering medical solutions for joints assessments. Emovi is dedicated to providing the highest quality, most technologically advanced products for knee joint assessment to restore patient quality of life. they are a company of knowledgeable, dedicated team members committed to innovation in healthcare.
Acer Therapeutics is a pharmaceutical company that focuses on the acquisition, development, and commercialization of therapies for serious, rare, and life-threatening diseases with unmet medical needs. Its pipeline includes four clinical-stage candidates: emetine hydrochloride for the treatment of patients with COVID-19; ACER-001 (a taste-masked, immediate-release formulation of sodium phenylbutyrate), for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); EDSIVO (celiprolol), for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and osanetant, for the treatment of induced Vasomotor Symptoms (iVMS). The company was founded in 2013 and is headquartered in Newton, Massachusetts.
Founded in 2011 by brothers Gabriel and Bernard Robichaud, Panthera Dental is a leader in prosthetic implant solutions and dental sleep appliances. Employing more than 50, the Québec City firm also has an office in New Jersey.
CENTOGENE is one of the largest genetic biotech companies worldwide, the European market leader, and one of the global leaders in genetic diagnostic analyses of rare inherited diseases. Transforming global genetic data into medical decisions, that are focused on creating broarder awareness for patients of all ethnicities around the world. CENTOGENE is a rare disease company focused on transforming clinical, genetic, and biochemical data into medical solutions for Patients. With headquarters in Rostock, Germany and further operations in Berlin, Germany as well as Cambridge, Massachusetts, USA, CENTOGENE is dedicated to transforming the science of genetic information into solutions and hope for patients with rare diseases and their families. CENTOGENE provides the full spectrum of modern methods and technology for human genetics analysis; it is active in research and is constantly developing new and innovative products for human genetics.
AL-S Pharma
Seed Round in 2016
AL-S Pharma AG develops AP-101, a human monoclonal antibody targeting misfolded SOD1 for the treatment of ALS.
Ixchelsis Ltd is a clinical-stage biotechnology company developing an oxytocin receptor antagonist (IX-01) for the treatment of premature ejaculation (PE). IX-01 is a clinical stage asset that has the potential to be the best in class pharmacological approach for the treatment of PE. To date IX-01 has completed a Phase 1 single ascending dose study in healthy male volunteers and is currently being progressed through to clinical proof of concept (POC). Ixchelsis is funded by TVM Life Sciences Ventures VII and is lead by an excellent Management team with extensive experience in pharmaceutical R&D, particularly in the male sexual health therapeutic area.
AurKa Pharma is a special purpose company created to develop one compound to proof-of-concept. To date, the biopharmaceutical asset has completed GLP toxicology studies.it plans to begin clinical development in Q3-2017. Once cleared for clinical development by regulatory authorities, the it compound will be tested directly alone in solid tumors. Later on, the compound may be tested in one of a number of additional cancer indications with the goal of providing a clinical proof-of-concept of efficacy for cancer patients.
Acer Therapeutics is a pharmaceutical company that focuses on the acquisition, development, and commercialization of therapies for serious, rare, and life-threatening diseases with unmet medical needs. Its pipeline includes four clinical-stage candidates: emetine hydrochloride for the treatment of patients with COVID-19; ACER-001 (a taste-masked, immediate-release formulation of sodium phenylbutyrate), for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); EDSIVO (celiprolol), for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and osanetant, for the treatment of induced Vasomotor Symptoms (iVMS). The company was founded in 2013 and is headquartered in Newton, Massachusetts.
leon nanodrugs a specialised product development company dedicated to developing a pipeline of enhanced versions of existing drug products, and providing services to enable pre-clinical and clinical stage formulations for their clients NCEs or branded established drugs. leon-nanodrugs offers access to the next generation of nano-formulated drugs with meaningful differentiation and added patient benefits. They specialize in improving the bioavailability of poorly water soluble drugs by using leon’s proprietary MJR® Technology platform to create either polymeric or crystalline nanoparticles.
Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration. The company was formerly known as Genomic Profiling Systems and changed its name to Rapid Micro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts.
Esperas Pharma
Venture Round in 2015
Esperas Pharma is a special purpose company created to develop one compound to proof-of-concept.
CoLucid Pharmaceuticals, Inc., a biotechnology company, focuses on therapies for central nervous system disorders. The company develops COL-144, a neurally acting anti-migraine agent, which is designed to treat migraine; and COL-204, a conjugated stigmine platform that produces novel chemical entities for therapy of sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. CoLucid Pharmaceuticals was founded in 2005 and is based in Research Triangle Park, North Carolina.
Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration. The company was formerly known as Genomic Profiling Systems and changed its name to Rapid Micro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts.
invendo medical aims to become a globally leading developer and distributor of disposable, highly flexible and easy-to-use endoscopy products in the field of gastroenterology. Innovation activity in gastroenterological endoscopy has in the past decades nearly exclusively focused on the improvement of optical capabilities. However, invendo medical´s goal is to improve patient compliance and thereby increase the number of procedures performed.
F-Star Therapeutics is a biopharmaceutical company dedicated to developing novel bispecific antibody products that provide a significant improvement over the current standard of care. Given its strong patent position, it is the only biopharmaceutical company with the ability to create and develop Fcab:tm: antibody fragments, and bispecific antibodies, by modifying the constant region of an antibody. In particular, F-star’s Modular Antibody Technology:tm: enables rapid discovery and development of bispecific antibodies by introducing additional binding sites to the constant region of an antibody and offers unprecedented ease in the development and manufacturing of bispecific monoclonal antibodies. Using the Modular Antibody Technology, F-star generates bispecific antibodies (mAb2:tm:) that possess the favourable characteristics of traditional monoclonal antibodies, without the production challenges often associated with other antibody formats. F-star is now applying its proprietary technology to the development of a pipeline of product candidates. Since its founding in 2006 the company has secured funding and support from leading VC investors: Aescap Venture, Atlas Venture, Novo Ventures and TVM Capital; as well as from renowned strategic corporate investors: Merck Serono Ventures, MP Healthcare Venture Management and SR One. In 2013, F-star established an asset-centric vehicle structure through the formation of F-star Alpha Ltd., which included out-licensing of FS102 from F-star to F-star Alpha Ltd. In October 2014 Bristol-Myers Squibb obtained an exclusive option to buy F-star Alpha. In addition the company has alliances with Boehringer Ingelheim and Merck Serono, each covering multiple targets. In 2011, F-star was selected by FierceBiotech as one of the Fierce 15 winners. F-star currently employs over 35 people at its research site in Cambridge, UK.
Ixchelsis Ltd is a clinical-stage biotechnology company developing an oxytocin receptor antagonist (IX-01) for the treatment of premature ejaculation (PE). IX-01 is a clinical stage asset that has the potential to be the best in class pharmacological approach for the treatment of PE. To date IX-01 has completed a Phase 1 single ascending dose study in healthy male volunteers and is currently being progressed through to clinical proof of concept (POC). Ixchelsis is funded by TVM Life Sciences Ventures VII and is lead by an excellent Management team with extensive experience in pharmaceutical R&D, particularly in the male sexual health therapeutic area.
Definiens is the provider of image analysis and data mining solutions for quantitative digital pathology in the life sciences, diagnostic biomarkers and healthcare industries. Definiens software provides detailed readouts from whole tissue slides, cell-based assays and full body scans and allows correlating this information with data derived from other sources. By automating analysis workflows, Definiens helps pharmaceutical and biotechnology companies, research institutions, clinical service organizations and pathologists to generate new knowledge and supports better decisions in research, diagnostics and therapy. Definiens’ vision is to open new fields of research, to contribute to development of personalized medicine and to significantly improve the quality of patients’ lives. Definiens is headquartered in Munich, Germany, and has offices throughout the United States.
Argos Therapeutics, Inc., a biotechnology company, engages in developing immunotherapy treatments for cancer, infectious and autoimmune diseases, and transplantation rejection. The company has clinical trial programs in cancer and human immunodeficiency virus. Its products include AGS-0031 for metastatic renal cell carcinoma; AGS-0041 for HIV; CD83 soluble protein for transplant rejection/autoimmune disorders; Anti IFN-alpha monoclonal antibody2 for lupus; and regulatory T cell therapy3 for autoimmune disorders. The company was formerly known as MERIX Bioscience, Inc. Argos Therapeutics was founded in 1997 and is based in Durham, North Carolina.
Vivoryon Therapeutics is a Germany based biopharmaceutical company engaged in the activities of research and development, preclinical and clinical trials. It is focused on the development of therapeutic products for the treatment of Alzheimer's disease and cancer. The company's pipeline products includes PQ912, PQ1565 and PQ-family.
F-Star Therapeutics is a biopharmaceutical company dedicated to developing novel bispecific antibody products that provide a significant improvement over the current standard of care. Given its strong patent position, it is the only biopharmaceutical company with the ability to create and develop Fcab:tm: antibody fragments, and bispecific antibodies, by modifying the constant region of an antibody. In particular, F-star’s Modular Antibody Technology:tm: enables rapid discovery and development of bispecific antibodies by introducing additional binding sites to the constant region of an antibody and offers unprecedented ease in the development and manufacturing of bispecific monoclonal antibodies. Using the Modular Antibody Technology, F-star generates bispecific antibodies (mAb2:tm:) that possess the favourable characteristics of traditional monoclonal antibodies, without the production challenges often associated with other antibody formats. F-star is now applying its proprietary technology to the development of a pipeline of product candidates. Since its founding in 2006 the company has secured funding and support from leading VC investors: Aescap Venture, Atlas Venture, Novo Ventures and TVM Capital; as well as from renowned strategic corporate investors: Merck Serono Ventures, MP Healthcare Venture Management and SR One. In 2013, F-star established an asset-centric vehicle structure through the formation of F-star Alpha Ltd., which included out-licensing of FS102 from F-star to F-star Alpha Ltd. In October 2014 Bristol-Myers Squibb obtained an exclusive option to buy F-star Alpha. In addition the company has alliances with Boehringer Ingelheim and Merck Serono, each covering multiple targets. In 2011, F-star was selected by FierceBiotech as one of the Fierce 15 winners. F-star currently employs over 35 people at its research site in Cambridge, UK.
AbIONYX Pharma is a biotechnology company that is focused on providing innovative therapies for indications without effective or existing treatments, even the rarest ones. They provide drugs for the treatment of renal and ophthalmological diseases on a daily basis.
Helomics® is a comprehensive personalized healthcare company, bringing the next generation of diagnostics to the oncology field. Helomics is dedicated to improving patient outcomes by providing a personalized comprehensive tumor profile utilizing a proprietary set of laboratory platforms that leverage both tissue-based live and fixed cellular based analysis allowing physicians to characterize malignant tumors on a personalized basis. Helomics’ novel molecular and cellular markers and bioinformatics services support treatment decisions by providing vital information based on the specific biological processes of each individual’s cancer.
VPIsystems (formerly VPI Virtual Photonics) develops and markets network planning software and services for the telecommunications industry in the United States and internationally. Its products include Photonic Design Automation, a solution for the modeling and optimization of photonic components and subsystems; and OnePlan, an integrated network planning system that enables communications service providers, systems integrators, and manufacturers to design, plan, and implement their transition to an IP-based network. The company serves wireline, wireless, and broadband carriers; and network equipment manufacturers and optical equipment vendors. VPIsystems, Inc. has strategic alliances with Accenture, HP, Logica, and Tech Mahindra. The company was founded as VPI Virtual Photonics, Inc. in 1997 and changed its name to VPIsystems, Inc. in July 2001. VPIsystems, Inc. is based in Holmdel, New Jersey with additional offices in Europe, Asia, and Australia.
Bluebird bio is a clinical-stage biotechnology company that develops gene therapies for severe genetic and rare diseases. The company's gene therapy procedures aim to genetically modify a patient's cells to fundamentally correct or address the genetic basis underlying a disease. Bluebird's revenue is derived from collaboration arrangements, research fees, license fees, and grant revenue. The company works with industry peers, strategic partners, and nonprofit organizations for the development and commercialization of its product candidates.
Arteris is a leading provider of system IP for the acceleration of system-on-chip (SoC) development across today’s electronic systems. Arteris network-on-chip (NoC) IP technology and SoC integration automation software enable higher product performance with lower power consumption and faster time to market, delivering better SoC economics so its customers can focus on dreaming up what comes next. Learn more at arteris.com.
Vivoryon Therapeutics is a Germany based biopharmaceutical company engaged in the activities of research and development, preclinical and clinical trials. It is focused on the development of therapeutic products for the treatment of Alzheimer's disease and cancer. The company's pipeline products includes PQ912, PQ1565 and PQ-family.
Ubidyne was formed in 2005 to bring its groundbreaking digital Antenna Embedded Radioâ„¢ technology to market. Ubidyne's products will be available from Nokia Siemens Networks as part of their Flexistation product family. The Ubidyne integrated active antenna systems are compatible with CPRI and OBSAI optical interfaces and support current and next-generation standards including GSM, UMTS, HSPA+, and LTE. Ubidyne's micro-radio technology is integrated within wireless antennas and revolutionizes the economics of mobile communications. This eliminates the need for coaxial feeder cables, remote electrical tilt and additional amplifiers on antenna towers and masts. The Ubidyne technology significantly reduces energy consumption while improving radio performance, deployment flexibility, coverage and capacity of mobile communications networks globally.
Cambridge Broadband designs wireless back-haul and access provisions that improve telecommunication network capacity and efficiency under increasing mobile data growth. The company's wireless back-haul and access provisions offers carrier-class, point-to-multipurpose broadband wireless access equipment, enabling telecom and mobile operators to accelerate customers' return on investment.
ReVolt Technology is a technology company, which is developing a rechargeable zinc-air battery. ReVolt's batteries may enable more high-power consumer devices, electric vehicles and renewable energy storage. The technology is a result of six years of intense research and development at SINTEF (the largest independent research institute in Scandinavia). Research on material combinations has solved issues historically related to the metal-air technology; power, lifetime and rechargeability.
ExtendMedia provides software and media services that enable content providers and distributors to quickly and securely create, deliver, manage & monetize online content offerings over many devices. Their flagship product, OpenCASE, is a trusted foundation on which providers are building their digital media businesses. ExtendMedia has over 16 years of experience working closely with the world's most successful and innovative communications and media companies. Their in-depth knowledge has been built into OpenCASE: an open architecture for integration with existing systems; features for skillful automation of even the largest content delivery systems to increase efficiency; and support for flexible business models.
Silicon Hive BV supplies semiconductor intellectual properties. It designs, builds, and licenses application-specific system solutions for use in consumer electronics and mobile terminals applications by semiconductor manufacturers and original equipment manufacturers. The company’s products enable semiconductor and consumer electronics companies to make programmable integrated circuits for imaging, video, and wireless communication applications. Silicon Hive BV’s solutions and parallel processor technologies are used in camera systems, video systems, and wireless communications. The company was founded in 2003 and is based in Eindhoven, the Netherlands with additional offices in San Jose, California; Tokyo, Japan; Seoul, South Korea; and Bangalore, India. Silicon Hive BV operates independently of Koninklijke Philips Electronics NV as of April 16, 2007.
Arteris is a leading provider of system IP for the acceleration of system-on-chip (SoC) development across today’s electronic systems. Arteris network-on-chip (NoC) IP technology and SoC integration automation software enable higher product performance with lower power consumption and faster time to market, delivering better SoC economics so its customers can focus on dreaming up what comes next. Learn more at arteris.com.
Transave
Series D in 2008
Transave, Inc., a biotechnology company, develops inhaled pharmaceuticals for the treatment of lung diseases. The company’s liposomal technology allows the release of drug in the lung's microenvironment. Its products also include Arikace for the treatment of gram-negative lung infections and pseudomonas infections in cystic fibrosis patients; and cisplatin lipid complex for the treatment of cancers affecting the lungs. Transave, Inc. was founded in 1997 and is headquartered in Monmouth Junction, New Jersey. As of December 1, 2010, Transave, Inc. operates as a subsidiary of Insmed Incorporated.
CoreOptics is the leading providers of 10G and 40G Distortion Tolerant Transponder Modules and IC solutions for Metro, Regional and Long Haul optical & data networking markets.With a belief that optical communications networks must become open systems that economically transmit information regardless of data rate or fiber types, CoreOptics provides the only field-proven MLSE-based equalization solutions on the market today. This innovative technology helps Tier 1 systems vendors and carriers deploy the next generation of high-performance networks using their existing fiber infrastructure. CoreOptics' 10G and 40G Distortion Tolerant Transponder Modules eliminate the need for Optical Compensators and the respective Second Stage Amplifiers, allowing customers to reduce their first-in deployment cost by up to 30%.
Albireo Pharma is a rare disease company dedicated to the discovery and development of novel bile acid modulators for the treatment of pediatric and adult liver diseases.
Vivendy Therapeutics Ltd. has developed a specific recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that is specifically modified to improve enzyme activity - enhancing the efficacy of the therapy in MPS IVA significantly
Enigma Semiconductor is developing next generation silicon solutions to enable the future of wired communications. Their solutions push the limits of technology to create compelling components and subsystems for applications such as Metropolitan and Access Networks, Enterprise and internet infrastructure and Storage Systems. Enigma is managed and stalled by a team of experienced professionals from established names like Cisco, intel and Vitesse Semiconductor.
Proteon Therapeutics, Inc is a biopharmaceutical company developing pharmaceuticals to address the medical needs of patients with renal and vascular diseases. The company leverages a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics. Proteon Therapeutics’ first drug candidate (PRT-201) is in development for the improvement of blood flow following vascular surgery procedures. The company’s initial clinical focus is vascular access for hemodialysis and peripheral arterial disease (PAD).
Netviewer GmbH manufactures and provides Web conferencing solutions. Its products enable users to view and edit documents jointly over the Internet. The company provides Netviewer Meet that lets the client to use the Internet to hold meetings; and Netviewer Support for internal and external customers. Its Netviewer Meet has application in project collaborations, live demos, and training. The company also offers Netviewer Admin that performs administrative tasks without involving another person; Netviewer Present that has provides online meetings for participants; online education, training, and informational events; Webinars to promote sales and customer loyalty; and conventions over the Internet. It offers its products as software-as-a-service option. The company was founded in 2001 and is headquartered in Karlsruhe, Germany. It has subsidiary operations in Thalwil, Switzerland; Levallois-Perret, France; Surrey, the Great Britain; the United States; Amsterdam, the Netherlands; Wien, Austria; Milano, Italy; Spain; Poland; Scandinavia; Stockholm, Sweden; and Karlsruhe, Germany.
Silicon Hive BV supplies semiconductor intellectual properties. It designs, builds, and licenses application-specific system solutions for use in consumer electronics and mobile terminals applications by semiconductor manufacturers and original equipment manufacturers. The company’s products enable semiconductor and consumer electronics companies to make programmable integrated circuits for imaging, video, and wireless communication applications. Silicon Hive BV’s solutions and parallel processor technologies are used in camera systems, video systems, and wireless communications. The company was founded in 2003 and is based in Eindhoven, the Netherlands with additional offices in San Jose, California; Tokyo, Japan; Seoul, South Korea; and Bangalore, India. Silicon Hive BV operates independently of Koninklijke Philips Electronics NV as of April 16, 2007.
ExtendMedia provides software and media services that enable content providers and distributors to quickly and securely create, deliver, manage & monetize online content offerings over many devices. Their flagship product, OpenCASE, is a trusted foundation on which providers are building their digital media businesses. ExtendMedia has over 16 years of experience working closely with the world's most successful and innovative communications and media companies. Their in-depth knowledge has been built into OpenCASE: an open architecture for integration with existing systems; features for skillful automation of even the largest content delivery systems to increase efficiency; and support for flexible business models.
Cambridge Broadband designs wireless back-haul and access provisions that improve telecommunication network capacity and efficiency under increasing mobile data growth. The company's wireless back-haul and access provisions offers carrier-class, point-to-multipurpose broadband wireless access equipment, enabling telecom and mobile operators to accelerate customers' return on investment.
Hymite is a venture funded product company bringing to market the next generation packaging platform for use with High Power (HP) / Ultra-high Brightness (UHB) LEDs. Hymite's Engineered Silicon (Si) package platform delivers new levels of performance and value to their customers developing products for Solid State Lighting applications.
Concert Pharmaceuticals is a clinical-stage biotechnology company dedicated to creating new medicines through a novel scientific approach utilizing the naturally-occurring element deuterium. Concert applies its innovative precision deuterium chemistry platform to modify specific properties of validated drug molecules, yielding a rich pipeline of new chemical entities (NCEs). Concert leverages decades of pharmaceutical experience to create novel drug candidates with the potential for efficacy and safety, while greatly reducing R&D risk, time, and expense.
AbIONYX Pharma is a biotechnology company that is focused on providing innovative therapies for indications without effective or existing treatments, even the rarest ones. They provide drugs for the treatment of renal and ophthalmological diseases on a daily basis.
RenaMed Biologics
Venture Round in 2006
RenaMed Biologics a biotechnology company, engages in the development and commercialization of therapies for the treatment of diseases associated with compromised kidney function. The company focuses on patients suffering from acute renal failure and additional indications where kidney function is compromised. It develops RBI-01, which utilizes physiologically active human renal epithelial cells and administered ex vivo, to replace and maintain severely compromised, or lost kidney functions due to illness, or trauma. The company was founded in 1995 as Nephros Therapeutics, Inc. and changed its name to RenaMed Biologics, Inc. in 2005. RenaMed Biologics, Inc. is based in Lincoln, Rhode Island.
CoreOptics is the leading providers of 10G and 40G Distortion Tolerant Transponder Modules and IC solutions for Metro, Regional and Long Haul optical & data networking markets.With a belief that optical communications networks must become open systems that economically transmit information regardless of data rate or fiber types, CoreOptics provides the only field-proven MLSE-based equalization solutions on the market today. This innovative technology helps Tier 1 systems vendors and carriers deploy the next generation of high-performance networks using their existing fiber infrastructure. CoreOptics' 10G and 40G Distortion Tolerant Transponder Modules eliminate the need for Optical Compensators and the respective Second Stage Amplifiers, allowing customers to reduce their first-in deployment cost by up to 30%.
Proteon Therapeutics, Inc is a biopharmaceutical company developing pharmaceuticals to address the medical needs of patients with renal and vascular diseases. The company leverages a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics. Proteon Therapeutics’ first drug candidate (PRT-201) is in development for the improvement of blood flow following vascular surgery procedures. The company’s initial clinical focus is vascular access for hemodialysis and peripheral arterial disease (PAD).
Cambridge Broadband designs wireless back-haul and access provisions that improve telecommunication network capacity and efficiency under increasing mobile data growth. The company's wireless back-haul and access provisions offers carrier-class, point-to-multipurpose broadband wireless access equipment, enabling telecom and mobile operators to accelerate customers' return on investment.
Newron Pharmaceuticals S.p.A. is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. Xadago® (safinamide) has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland and the USA, and is commercialized by Newron’s Partner Zambon. US WorldMeds holds the commercialization rights in the USA. Meiji Seika, in collaboration with Eisai, has the rights to develop and commercialize the compound in Japan and other key Asian territories. In addition to Xadago® for Parkinson’s disease, Newron has a strong pipeline of promising treatments for rare disease patients at various stages of clinical development, including sarizotan for patients with Rett syndrome and ralfinamide for patients with specific rare pain indications. Newron is also developing Evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia. Founded in 1999, Newron is headquartered in Bresso, near Milan, Italy, with a subsidiary in Morristown, NJ, USA. The Company is listed on the SIX Swiss Exchange, trading symbol NWRN.
Impress Software Solutions, Inc. provides packaged integration applications for the integration of project management and geographical information systems with SAP. The company’s products include Impress for EPM, a packaged integration application for bridging SAP PM/PS with Microsoft project or Primavera, which synchronizes project-related data between the systems; and Impress for GIS, a packaged integration application, which links SAP assets with GIS features and keeps the asset information in synch between systems. It offers solutions in the areas of plant turnarounds, routine maintenance, information technology and capital projects, and spatial asset management. The company serves energy and utilities, oil and gas, aerospace and defense, chemicals, and engineering and construction industries. It has strategic partnership with Accenture, ESRI, Microsoft, Primavera, and SAP. The company was founded in 1997 and is based in Waltham, Massachusetts with additional offices in Hannover, Germany; and Huizerstraatweg, the Netherlands. Impress Software Solutions, Inc operates as a subsidiary of Impress Software Gmbh.
WILEX a biopharmaceutical company, develops drugs and diagnostic agents to detect cancer, treat malignant tumours, and prevent metastases. Its product line includes RENCAREX, a phase III substance for the treatment of non-metastatic renal cell cancer; REDECTANE, a phase III substance for the treatment of renal mass; and MESUPRON, a phase II substance for the treatment of pancreatic and breast cancer. The company's products also comprise the MEK inhibitor WX-554, which is under Phase I clinical trial; and the other oncology projects, including PI3K inhibitor WX-037 and three antibody programmes under preclinical development. It has a strategic alliance with UCB Pharma S.A. to develop preclinical oncology portfolio. The company was founded in 1997 and is headquartered in Munich, Germany.
[Sirtris Pharmaceuticals](http://www.sirtrispharma.com) (NASDAQ: SIRT) is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. via: [Sirtris](http://www.sirtrispharma.com)
VPIsystems (formerly VPI Virtual Photonics) develops and markets network planning software and services for the telecommunications industry in the United States and internationally. Its products include Photonic Design Automation, a solution for the modeling and optimization of photonic components and subsystems; and OnePlan, an integrated network planning system that enables communications service providers, systems integrators, and manufacturers to design, plan, and implement their transition to an IP-based network. The company serves wireline, wireless, and broadband carriers; and network equipment manufacturers and optical equipment vendors. VPIsystems, Inc. has strategic alliances with Accenture, HP, Logica, and Tech Mahindra. The company was founded as VPI Virtual Photonics, Inc. in 1997 and changed its name to VPIsystems, Inc. in July 2001. VPIsystems, Inc. is based in Holmdel, New Jersey with additional offices in Europe, Asia, and Australia.
Aventeon, Inc. provides mobile enterprise software solutions. It develops software applications and middleware that are designed to streamline processes that connect mobile client device users with the back-end ERP systems of their organizations. The company offers applications for the functional areas of sales, service, and logistics, as well as various industry vertical applications, such as utility, transport and logistics, manufacturing, telecom, retail, pharmaceutical, and health care industry. Aventeon, Inc. was formerly known as Aventeon GmbH. The company was founded in 2000 and is based in Munich, Germany with additional offices in Seattle, Washington; Culemborg, the Netherlands; and Hyderabad, India.
VPIsystems (formerly VPI Virtual Photonics) develops and markets network planning software and services for the telecommunications industry in the United States and internationally. Its products include Photonic Design Automation, a solution for the modeling and optimization of photonic components and subsystems; and OnePlan, an integrated network planning system that enables communications service providers, systems integrators, and manufacturers to design, plan, and implement their transition to an IP-based network. The company serves wireline, wireless, and broadband carriers; and network equipment manufacturers and optical equipment vendors. VPIsystems, Inc. has strategic alliances with Accenture, HP, Logica, and Tech Mahindra. The company was founded as VPI Virtual Photonics, Inc. in 1997 and changed its name to VPIsystems, Inc. in July 2001. VPIsystems, Inc. is based in Holmdel, New Jersey with additional offices in Europe, Asia, and Australia.
[Sirtris Pharmaceuticals](http://www.sirtrispharma.com) (NASDAQ: SIRT) is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. via: [Sirtris](http://www.sirtrispharma.com)
Aventeon, Inc. provides mobile enterprise software solutions. It develops software applications and middleware that are designed to streamline processes that connect mobile client device users with the back-end ERP systems of their organizations. The company offers applications for the functional areas of sales, service, and logistics, as well as various industry vertical applications, such as utility, transport and logistics, manufacturing, telecom, retail, pharmaceutical, and health care industry. Aventeon, Inc. was formerly known as Aventeon GmbH. The company was founded in 2000 and is based in Munich, Germany with additional offices in Seattle, Washington; Culemborg, the Netherlands; and Hyderabad, India.
TransMolecular, Inc. is a neuroscience biotechnology company committed to discovering, developing and commercializing novel and proprietary drugs to diagnose and treat diseases of the central nervous system having inadequate pharmaceutical alternatives. The Company focuses its drug development on cancer and pain, and has built strong technology platforms to enrich its product discovery and development pipeline. Founded in July 1996, TransMolecular is privately held and venture capital backed, having raised $9.6MM to date through two private placements from internationally recognized investment firms. The Company has built a strong management team that is dedicated to the discovery and development of safe and effective products for patients suffering from cancer and pain. Its management team has more than 75 years of combined relevant experience in healthcare, pharmaceutical development, R&D, operations, and finance. TransMolecular's corporate offices and R&D laboratories are in Birmingham, Alabama. TransMolecular has received three Small Business Incentive Research (SBIR) grants totaling $1 million from the National Institutes of Health for its cancer and pain programs. The Company holds more than 25 patents and/or patent applications to protect its products worldwide, and has exclusive license agreements with the University of Alabama at Birmingham Research Foundation and Yale University for its cancer and pain technology, respectively.
Arrow Therapeutics was founded in 1998 and is already making a significant contribution to anti-infective drug discovery. Microbial resistance to existing drugs is an ever increasing threat that is leading to serious unmet medical need and incurring a huge financial burden on society. Despite the huge challenges of this situation it also presents excellent opportunities to combine scientific research and business. As more and more big pharma groups concentrate their efforts on drug development, greater chances are open to smaller companies such as ours to show their excellence in research.
VPIsystems (formerly VPI Virtual Photonics) develops and markets network planning software and services for the telecommunications industry in the United States and internationally. Its products include Photonic Design Automation, a solution for the modeling and optimization of photonic components and subsystems; and OnePlan, an integrated network planning system that enables communications service providers, systems integrators, and manufacturers to design, plan, and implement their transition to an IP-based network. The company serves wireline, wireless, and broadband carriers; and network equipment manufacturers and optical equipment vendors. VPIsystems, Inc. has strategic alliances with Accenture, HP, Logica, and Tech Mahindra. The company was founded as VPI Virtual Photonics, Inc. in 1997 and changed its name to VPIsystems, Inc. in July 2001. VPIsystems, Inc. is based in Holmdel, New Jersey with additional offices in Europe, Asia, and Australia.
Helomics® is a comprehensive personalized healthcare company, bringing the next generation of diagnostics to the oncology field. Helomics is dedicated to improving patient outcomes by providing a personalized comprehensive tumor profile utilizing a proprietary set of laboratory platforms that leverage both tissue-based live and fixed cellular based analysis allowing physicians to characterize malignant tumors on a personalized basis. Helomics’ novel molecular and cellular markers and bioinformatics services support treatment decisions by providing vital information based on the specific biological processes of each individual’s cancer.
Morphics Technology, Inc. is a communications systems company that supplies Wireless Signal Processors (WSPs) as off-the-shelf ICs for basestations and Intellectual Property (IP) Cores for handset and terminals products. Morphics combines expertise in communications theory, digital signal processing, computer architecture, and silicon engineering to cost-effectively deliver the highest levels of signal processing performance, as well as flexibility and scalability, for next generation wireless networks. For the wireless infrastructure market, Morphics supplies efficient off-the-shelf wireless signal processors (WSPs). Morphics’ WSPs address the cost-reduction needs of 3G basestation manufacturers by providing scalable baseband processing with industry-leading channel density. Such programmable WSPs enable equipment vendors to build in proprietary radio-link and network performance differentiation as well as to implement any of the leading 3G wireless standards.
TransMolecular, Inc. is a neuroscience biotechnology company committed to discovering, developing and commercializing novel and proprietary drugs to diagnose and treat diseases of the central nervous system having inadequate pharmaceutical alternatives. The Company focuses its drug development on cancer and pain, and has built strong technology platforms to enrich its product discovery and development pipeline. Founded in July 1996, TransMolecular is privately held and venture capital backed, having raised $9.6MM to date through two private placements from internationally recognized investment firms. The Company has built a strong management team that is dedicated to the discovery and development of safe and effective products for patients suffering from cancer and pain. Its management team has more than 75 years of combined relevant experience in healthcare, pharmaceutical development, R&D, operations, and finance. TransMolecular's corporate offices and R&D laboratories are in Birmingham, Alabama. TransMolecular has received three Small Business Incentive Research (SBIR) grants totaling $1 million from the National Institutes of Health for its cancer and pain programs. The Company holds more than 25 patents and/or patent applications to protect its products worldwide, and has exclusive license agreements with the University of Alabama at Birmingham Research Foundation and Yale University for its cancer and pain technology, respectively.
eCustomers, Inc. is revolutionizing the way consumers interact with businesses online. To empower consumers, eCustomers, Inc. was created to be a pioneer and leading Internet-based infomediary that delivers valuable personalized content to eBusiness systems.
eCustomers, Inc. is revolutionizing the way consumers interact with businesses online. To empower consumers, eCustomers, Inc. was created to be a pioneer and leading Internet-based infomediary that delivers valuable personalized content to eBusiness systems.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.